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Table 1
Biomarkers Hazard Ratio (95% CI)
uNTX-I 1.80 (0.83, 3.90
uCTX-II 2.28 (1.00, 5.16)
uC2C 1.06 (0.57, 1.97)
uC1,2C 1.29 (0.88, 1.89)
sHA 1.44 (0.79, 2.63)
sCS846 1.32 (0.49, 3.56)
Abstracts / Osteoarthritis and Cartilage 21 (2013) S63–S312S156between BP use and age, sex, joint replaced (hip/knee), and prior frac-
ture on outcome by introducing multiplicative terms in the equation.
Results: 80,342/95,392 (84.2%) subjects were eligible. We identiﬁed
1,950 (2.4%) BPU, and 1,911 (98.0%) of them were matched to 10,755
BPNU. In total, 226/12,666 (1.78%) of the participants (22/1,911 BPU and
204/10,755 matched BPNU) underwent revision surgery during study
follow-up (median 1.11 years, inter-quartile range 0.43-2.29 years).
Cox regression models showed reduced revision risk in BP users
(propensity-matched HR 0.59; 95% Conﬁdence Interval (CI) [0.37-0.94])
[Figure], which remained signiﬁcant after multivariable adjustment for
unbalanced covariates (adjusted HR 0.59; 95% CI [0.37-0.93]). This
protective effect was only seen in BPU who initiated treatment post-
operatively (adjusted HR 0.36 ; 95% CI [0.15-0.84]) and not in those
starting pre-op (adjusted HR 0.77; 95% CI [0.44-1.35]), and who
remained on treatment for at least one year: adjusted HR 0.50; 95% CI
[0.27-1.00] for those treated for 1-2 years compared to adjusted HR
1.29; 95% CI (0.80-2.08) in those treated for 6-12 months. Patients with
the highest adherence beneﬁted the most (adjusted HR 0.53; 95% CI
(0.30-0.95)) in BPU with MPR>0.8).
The effect of BPU on implant survival was not modiﬁed by age, gender,
fracture history or joint replaced (all p for interactions>0.2).
Conclusions: BPU are at 40% reduced risk of revision compared to
matched BPNU. These results are similar to previous ﬁndings using
similar retrospective data from the UK [Prieto-Alhambra D et al. BMJ
2011]. Conﬁrmation of these beneﬁcial effects in formal randomized
controlled trials is urgently needed.Ă
sCPII 0.58 (0.34, 0.99)
sCOMP 2.58 (0.48, 13.90)
sC2C 0.53 (0.15, 1.87)
sC1,2C 1.61 (0.52, 4.94)
uCTX-II/sCPII 1.78 (1.17, 2.72)
uC2C/sCPII 1.44 (0.93, 2.21)
uC1,2C/sCPII 1.52 (1.08, 2.16)
sC2C/sCPII 2.15 (1.05, 4.39)293
ASSOCIATION OF BIOMARKERS WITH OSTEOARTHRITIS
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Purpose: To determine the association of biomarkers with progression
of osteoarthritis (OA), based on MRI, in a population-based cohort of
predominantly pre-radiographic disease.
Methods: Population-based longitudinal cohort study of subjects, age
40 to 79, with knee pain. Subjects were evaluated at baseline and
follow-up (FU) using detailed clinical assessments, knee x-ray, MRI
(1.5T) and biomarkers. MRI of cartilage (MRC) was scored 0-4 on six
joint surfaces. Progression was deﬁned on MRI as an increase in MRC
score of 1 grade on at least 2 cartilage surfaces or an increase of MRC
score of 2 grades on at least 1 cartilage surface. Urine biomarkers
included C-telopeptide of type II collagen (uCTX-II) (Nordic Bioscience),
type II and type I and II collagen cleavage neoepitopes (uC2C, uC1,2C)
(Ibex), N-telopeptide of type I collagen (uNTX-I) (Ostex). Serum
biomarkers included sC1,2C, sC2C, c-propeptide of type II procollagen(sCPII), 846 epitope (sCS846) (Ibex), cartilage oligomeric matrix protein
(sCOMP) (AnaMar) and hyaluronic acid (sHA) (Corgenix). Ratios of type
II collagen degradation with synthesis markers were also evaluated.
Biomarker data were log transformed. Exponential regression analysis
was used to determine the association of each biomarker with OA
progression, adjusted for age, gender, BMI and joint count. All analyses
utilized longitudinal stratum sampling weights to ensure generaliz-
ability of results.
Results: Of 255 subjects seen at baseline, 163 (63.9%) were assessed at
a median FU of 3.2 years (range 2.5-5.1). Of these, 60.6% had KL grade
<2, mean age was 57.6 years. MRI progression was present in 15.5% of
subjects. Biomarkers signiﬁcantly associated with OA progression
included uCTX-II (HR 2.28; 95% CI 1.00, 5.16), sCPII (HR 0.58; 95% CI 0.34,
0.99), as well as ratios of uCTX-II/sCPII (HR 1.78; 95% CI 1.17, 2.72),
uC1,2C/sCPII (HR 1.52; 95% CI 1.08, 2.16) and sC2C/sCPII (HR 2.15; 95% CI
1.05, 4.39) (Table 1).Conclusions: In this population-based cohort of predominantly pre-
radiographic knee OA, uCTX-II and sCPII were both signiﬁcantly asso-
ciated with OA progression. As well, ratios of uCTX-II/sCPII, uC1,2C/sCPII
and sC2C/sCPII were signiﬁcantly associated with OA progression with
similar strengths of association. These biomarkers may be useful in
future studies aimed at evaluating OA disease progression in epidemi-
ologic studies and clinical trials.
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Purpose: To determine the clinical predictors of osteoarthritis (OA)
progression based on cartilage damage on MRI in a population-based
cohort of predominantly pre-radiographic knee OA and to develop
a simpliﬁed model to identify those at risk of progression with high
speciﬁcity for practical application in clinical trials.
Methods: Population-based longitudinal cohort study of subjects, age
40 to 79, with knee pain. Subjects were evaluated at baseline and
follow-up (FU) using detailed clinical assessments, standardized knee
examination, ﬁxed-ﬂexion knee x-ray and MRI (1.5T). X-rays were read
for Kellgren-Lawrence (KL) 0-4 grade. MRI of cartilage (MRC) was
scored 0-4 on six joint surfaces by a blinded reader. OA progression was
deﬁned on MRI as an increase in MRC score of 1 grade on at least 2
cartilage surfaces or an increase in MRC score of 2 grades on at least 1
cartilage surface. Exponential regression analysis was used to develop
a prediction model for OA progression. The model was evaluated based
on prediction accuracy, Akaike's Information Criterion (AIC) and C-
index, where a 1.0 score indicates a perfect model ﬁt. The model was
then simpliﬁed by removing variables and evaluating the impact on the
model accuracy and C-index. All analyses utilized longitudinal stratum
sampling weights to maintain generalizability.
Results: Of 255 subjects seen at baseline, 163 (63.9%) were assessed at
a median FU of 3.2 years (range 2.5-5.1). Of these, 60.6% had KL grade
